Healthcare / Health Information ServicesTokyo
$1684.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $719.8M · quality 39.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$63.8B
P/E
227.3x
↑EV/EBITDA
135.4x
↑ROE
9.1%
↑Gross Margin
69.6%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.3%
FCF CAGR
-5.7%
FCF margin
11.0%
FCF / Net income
2.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.54B · net income $280.2M · FCF $719.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.54B | $6.54B | $5.91B | $6.42B | $6.10B |
| Net Income | $280.2M | $280.2M | $-791.2M | $979.1M | $870.5M |
| EBITDA | $458.3M | $458.3M | $131.5M | $1.87B | $1.91B |
| EPS | — | — | -20.73 | 25.63 | 22.76 |
| Gross Margin | 69.6% | 69.6% | 73.3% | 78.4% | 82.4% |
| Operating Margin | 5.3% | 5.3% | 0.1% | 27.6% | 28.8% |
| Net Margin | 4.3% | 4.3% | -13.4% | 15.3% | 14.3% |
| Balance Sheet | |||||
| Current Ratio | 2.22 | 2.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $719.8M | $719.8M | $-1.03B | $1.59B | $857.6M |
| Returns | |||||
| ROE | 9.1% | 9.1% | -25.5% | 23.0% | 24.8% |
| Valuation | |||||
| P/E | 227.26 | 227.26 | — | 26.02 | 38.80 |
| EV/EBITDA | 135.38 | 135.38 | 103.81 | 11.88 | 16.51 |
| P/B | 20.68 | 20.68 | 4.84 | 5.99 | 9.61 |
| Growth & Yield | |||||
| Revenue Growth | 10.7% | 10.7% | -8.0% | 5.2% | — |
| EPS Growth | — | — | -180.9% | 12.6% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+311.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-20.73 → n/d
Residual
+310.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.